Questions about cancer? Freephone 1800 200 700 Irish Cancer Society Nurseline

About this trial

The purpose of this study is to investigate if Cemiplimab is better than placebo when a CSCC patient has been treated after they have had both surgery and radiotherapy. This is a Phase 3 trial. It is planned that the study’s primary completion date will be 16 OCT 2023, follow-up activities will continue until 11 FEB 2026.

Patient Profile

Adults aged 18 years and older, ECOG Performance status score ≤1

 

Where’s this trial being run?

Cork University Hospital and St Vincents University Hospital

Can I join this study / trial?

The first thing you do is to talk to your doctor and/or the cancer trials research team in your hospital. The contact details for the cancer trials research units in Ireland is here.

Why not Print this page and bring it with you. It will help your doctor and research team advise you.

For more detailed information

Questions?

Here’s a list of questions you may have for your doctor or local cancer research team.

Summary Data

Name: R2810-ONC-1788
Number: 18-50
Full Title:

A Randomized, Placebo-Controlled, Double-Blind Study of Adjuvant Cemiplimab Versus Placebo After Surgery and Radiation Therapy in Patients With High Risk Cutaneous Squamous Cell Carcinoma

Principal Investigator: Dr Derek Power
Type: Industry Sponsored
Sponsor:

Regeneron Pharmaceuticals

Recruitment Started: Global: 31 JUL 2019
Ireland: 24 JAN 2020
Global Recruitment Target: 412
Ireland Recruitment Target: 8